share_log

Exicure | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Exicure | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Exicure | NT 10-Q:季报延迟披露公告
美股sec公告 ·  05/15 16:52
Moomoo AI 已提取核心信息
Exicure, Inc. has announced that it will not meet the prescribed due date for filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The delay is due to the company's ongoing process of completing restatements for its financial statements for the first and second quarters of 2023, as well as the filing of related Form 10-Q amendments and its third quarter of 2023 financial statements. Additionally, Exicure needs to complete and file its Annual Report on Form 10-K for the year ended December 31, 2023. The company has not filed its third quarter 2023 10-Q and 2023 10-K reports. Significant changes in operations are anticipated in the upcoming earnings statements due to a major reduction in workforce, suspension of preclinical activities, and...Show More
Exicure, Inc. has announced that it will not meet the prescribed due date for filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The delay is due to the company's ongoing process of completing restatements for its financial statements for the first and second quarters of 2023, as well as the filing of related Form 10-Q amendments and its third quarter of 2023 financial statements. Additionally, Exicure needs to complete and file its Annual Report on Form 10-K for the year ended December 31, 2023. The company has not filed its third quarter 2023 10-Q and 2023 10-K reports. Significant changes in operations are anticipated in the upcoming earnings statements due to a major reduction in workforce, suspension of preclinical activities, and cessation of all research and development activities announced in September 2022. Exicure is also exploring strategic alternatives to maximize shareholder value. As a result of these changes, there are no research and development expenses reported for 2024, and general and administrative expenses are expected to be lower than the previous year. The notification was signed by CEO Paul Kang on May 15, 2024.
Exicure, Inc.宣布,它不会在规定的截止日期之前提交截至2024年3月31日的10-Q表季度报告。延迟是由于该公司正在完成2023年第一和第二季度的财务报表重报,以及相关的10-Q表修正案和2023年第三季度财务报表的提交。此外,Exicure需要填写并提交截至2023年12月31日止年度的10-K表年度报告。该公司尚未提交其2023年第三季度10季度和2023年10-K报告。由于员工队伍大幅裁员、暂停临床前活动以及2022年9月宣布停止所有研发活动,预计即将发布的收益报表中将出现重大运营变化。Exicure还在探索战略替代方案,以最大限度地提高股东价值。由于这些变化,没有报告2024年的研发费用,一般和管理费用预计将低于上一年。该通知由首席执行官保罗·康于2024年5月15日签署。
Exicure, Inc.宣布,它不会在规定的截止日期之前提交截至2024年3月31日的10-Q表季度报告。延迟是由于该公司正在完成2023年第一和第二季度的财务报表重报,以及相关的10-Q表修正案和2023年第三季度财务报表的提交。此外,Exicure需要填写并提交截至2023年12月31日止年度的10-K表年度报告。该公司尚未提交其2023年第三季度10季度和2023年10-K报告。由于员工队伍大幅裁员、暂停临床前活动以及2022年9月宣布停止所有研发活动,预计即将发布的收益报表中将出现重大运营变化。Exicure还在探索战略替代方案,以最大限度地提高股东价值。由于这些变化,没有报告2024年的研发费用,一般和管理费用预计将低于上一年。该通知由首席执行官保罗·康于2024年5月15日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息